Trial intelligence / Profile preview

Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations

jRCT2031220390Phase 2Completed

Sponsor

Blueprint Medicines

Start

Jan 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules